Cell/Gene Tx channel feed

Can­cer gi­ant Roche splash­es in­to cell ther­a­py with $3B+ Adap­ti­m­mune deal for off-the-shelf drugs

4 years ago
Deals

Liv­er tu­mors in an­i­mals trig­ger clin­i­cal hold for Bio­Marin gene ther­a­py — high­light­ing a re­cur­ring con­cern

4 years ago
FDA+

'A missed op­por­tu­ni­ty': The biggest take­aways from the FDA's un­der­whelm­ing gene ther­a­py hear­ing

4 years ago

The long-over­looked safe­ty is­sue weigh­ing on the FDA’s mind on day 1 of marathon gene ther­a­py meet­ing

4 years ago
FDA+

Sis­ter to Juno's liso-cel, JW's rel­ma-cel lands sec­ond-ever CAR-T ap­proval in Chi­na

4 years ago
China
FDA+

FDA posed a sprawl­ing set of ques­tions for two-day gene ther­a­py hear­ing. Here's what com­pa­nies and ex­perts will be watch­ing for

4 years ago
FDA+

Astel­las paus­es Au­den­tes' gene ther­a­py pro­gram again af­ter 'ab­nor­mal' liv­er tests in yet an­oth­er set­back

4 years ago
R&D

Mov­ing past a pa­tient death, Po­sei­da of­fers an ear­ly snap­shot of proof of ef­fi­ca­cy for a next-gen sol­id tu­mor CAR-T

4 years ago
R&D

Feng Zhang's lab de­vel­ops po­ten­tial break­through in RNA edit­ing de­liv­ery us­ing 'ul­tra­com­pact' ver­sions of Cas13

4 years ago
Discovery

Big mon­ey: Flag­ship's uber-plat­form play Laronde rakes in $440M to chase pro­gram­ma­ble 'eR­NA'

4 years ago
Financing

Ap­peals court sides with Gilead, Kite in CAR-T patent brawl, void­ing Bris­tol My­ers’ big $1.2B award

4 years ago
Pharma

No­var­tis' CAR-T fails to help a vul­ner­a­ble group of NHL pa­tients — quash­ing hope of mov­ing up lines of treat­ment

4 years ago
R&D

Cap­ping AAV dose? Tweak­ing gene ther­a­py tri­als? New an­i­mal mod­els? FDA pos­es far-reach­ing ques­tions for ex­perts

4 years ago
FDA+

Feng Zhang un­veils a new tech­nol­o­gy to po­ten­tial­ly de­liv­er mR­NA, gene ther­a­py, CRISPR and more

4 years ago
People
Discovery

Fate's close­ly watched stem cell-de­rived NK pro­gram rais­es red flag over dura­bil­i­ty of re­sponse

4 years ago
R&D

Search­ing for ways to boost CAR-T re­sponse, Penn re­searchers find a ca­pa­ble wing­man in BET in­hibitors

4 years ago
Discovery

FDA lifts clin­i­cal hold on Rock­et's gene ther­a­py for heart fail­ure af­ter 3-month de­lay

4 years ago
FDA+

Longeveron's cell ther­a­py flops ear­ly walk test study as ex­ecs tout flim­sy sup­port­ing da­ta

4 years ago

Mer­ck part­ner Arti­va blue­prints San Diego R&D, man­u­fac­tur­ing site to take NK cell op­er­a­tion to the next lev­el

4 years ago
Manufacturing

Bi­o­Life So­lu­tions sets up shop in In­di­anapo­lis, adding a slate of new cell and gene ther­a­py tools to its belt

4 years ago
Deals
Manufacturing

Blue­bird forced to halt tri­als af­ter a can­cer-like case, pulls gene ther­a­pies from Eu­rope fol­low­ing pric­ing back­lash — shares slammed

4 years ago
R&D
FDA+

FDA lifts year-plus hold on No­var­tis' Zol­gens­ma, set­ting the stage for new PhI­II

4 years ago
FDA+

Ad­verum faces murky fu­ture af­ter re­view turns up deep­er safe­ty is­sues for gene ther­a­py

4 years ago
R&D

Af­ter slic­ing and dic­ing TCRs for 8 years, Swedish biotech re­loads to an­gle for a spot in crowd­ed cell ther­a­py space

4 years ago
Financing
First page Previous page 36373839404142 Next page Last page
A service from the Financial Times